首页|生长激素治疗障碍评估量表的汉化及信效度检验

生长激素治疗障碍评估量表的汉化及信效度检验

扫码查看
目的:汉化生长激素治疗障碍评估量表(BAR-GHT),并检验其在矮小症病人中的信效度.方法:通过翻译、回译、文化调试和预实验,形成中文版BAR-GHT,选取接受生长激素治疗超过3个月的矮小症病人及其父母共216人进行问卷调查,验证其信效度.结果:中文版BAR-GHT包括父母版(5个维度,16个条目)和儿童/青少年版(5个维度,17个条目),量表的Cronbach's α系数分别为0.876和0.905,分半信度分别为0.852和0.793,重测信度分别为0.857和0.934;量表水平内容效度指数分别为0.921和0.933,与8项Morisky药物治疗依从性量表的校标关联效度为0.597和0.703(均P<0.01);探索性因子分析均提取出5个公因子,累计方差贡献率分别为82.442%和81.433%.结论:中文版BAR-GHT信效度良好,可用于评估我国矮小症病人生长激素治疗障碍水平.
Chinese translation and reliability and validity test of the Barriers to Growth Hormone Treatment
Objective:To localize the Barriers to Growth Hormone treatment(BAR-GHT)and test its reliability and validity in patients with dwarfism.Methods:Through translation,back-translation,cultural adjustment,and pre-experiment,the Chinese version of BAR-GHT was formed.A total of 216 patients with dwarfism who had received growth hormone treatment for more than 3 months and their parents were selected for the questionnaire survey to verify its reliability and validity.Results:The Chinese version of BAR-GHT included a parent version(16 items in 5 dimensions)and a child/adolescent version(17 items in 5 dimensions).The Cronbach's αcoefficients of the scales were 0.876 and 0.905,the split-half reliability was 0.852 and 0.793,and the test-retest reliability was 0.857 and 0.934,respectively.The scale-level content validity index was 0.921 and 0.933,and the criterion-correlated validity with the 8-item Morisky Medication Adherence Scale was 0.597 and 0.703(all P<0.01),respectively.Exploratory factor analysis extracted 5 common factors,and the cumulative variance contribution rates were 82.442%and 81.433%,respectively.Conclusions:The Chinese version of BAR-GHT has good reliability and validity,which can be used to assess the level of growth hormone treatment barriers among patients with dwarfism in China.

growth hormonetreatment barriersscaledwarfismreliabilityvalidity

王灵、王志敏、彭艳红、段巧艳、朱璐兰

展开 >

南华大学附属第二医院,湖南 421001

生长激素 治疗障碍 量表 矮小症 信度 效度

2025

循证护理

循证护理

ISSN:
年,卷(期):2025.11(1)